Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Transfer factor: a potential agent for cancer therapy

A F LoBuglio, J A Neidhart

The Medical Clinics of North America

|May 1, 1976

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.

Cancer biotherapy & radiopharmaceuticals·2001

Same author

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001

Same author

Expression of human endogenous retrovirus k envelope transcripts in human breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001

Same author

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer.

Cancer biotherapy & radiopharmaceuticals·2001

Same author

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2001

Same author

A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.

Seminars in oncology·2001

Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026

Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026

Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026

Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026

Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026

Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026

See all related articles

Transfer factor shows promise as an immunotherapy agent for various diseases, including cancer. Further research into its characteristics is essential for successful clinical applications and developing novel immunotherapeutic strategies.

Area of Science:

Immunology and immunotherapy research.
Molecular biology and cellular mechanisms.

Background:

Transfer factor is a potential immunotherapeutic agent.
Its characteristics are being explored for various applications.

Purpose of the Study:

To describe the characteristics of transfer factor.
To evaluate its potential as an immunotherapy agent.

Main Methods:

Review of existing literature on transfer factor.
Analysis of preliminary observations regarding its effects.

Main Results:

Transfer factor exhibits attractive characteristics for immunotherapy.
Preliminary data suggest efficacy against diseases like cancer.

Related Experiment Videos

Conclusions:

Understanding transfer factor's basic properties is crucial for clinical use.
Ongoing research may lead to new immunotherapy approaches.